Paper Details

  1. Home
  2. Paper Details

Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I.

Author: CzajaAlbert J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Mycophenolate mofetil is emerging as a rescue therapy for autoimmune hepatitis, improving patients with azathioprine intolerance more frequently (54%) than those with refractory liver disease (10%). 40% of patients who received mycophenolate mofetil were able to completely withdraw corticosteroids. Budesonide is emerging as a frontline treatment in non-cirrhotic patients with uncomplicated disease or contraindications to conventional corticosteroids.
Paper Details　
Original Abstract of the Article :
Nonstandard drugs that target critical pathogenic pathways or immune regulatory mechanisms constitute the next generation of treatments for autoimmune hepatitis. Mycophenolate mofetil impairs the proliferation of lymphocytes, decreases autoantibody production, and induces apoptosis of activated immu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/187152812803251006

データ提供：米国国立医学図書館（NLM）

Autoimmune Hepatitis: A Search for New Oasis in a Desert of Immune Dysfunction

Autoimmune hepatitis (AIH) is a chronic liver disease where the body's immune system mistakenly attacks its own liver cells. It's like a desert storm, wreaking havoc on a delicate ecosystem. Current treatments often involve corticosteroids, but these can have significant side effects. This review explores new, nonstandard drugs that target specific immune pathways, potentially offering a more targeted and safer approach to AIH management.

New Treatments: Emerging Oasis in the Desert of AIH

The review highlights promising new treatments for AIH, such as mycophenolate mofetil, budesonide, and cyclosporine. These drugs work by suppressing specific immune cells or pathways involved in the disease process. It's like finding new watering holes in the desert, providing relief from the harsh conditions. While these drugs are still under investigation, early results suggest they may offer more targeted and effective treatment options for AIH.

Hope for a Brighter Future in AIH Treatment

The emergence of nonstandard drugs for AIH offers a glimmer of hope for patients battling this challenging disease. These new therapies represent a shift towards a more individualized approach to treatment, focusing on specific immune mechanisms rather than broad-spectrum suppression. It's like finding a new route through the desert, offering a more tailored and effective path to recovery.

Dr. Camel's Conclusion

The search for new treatments for AIH is an ongoing journey through the vast desert of immune dysfunction. Nonstandard drugs offer promising new options, like hidden oases, providing hope for a more targeted and effective approach to managing this complex disease.

Date :
  1. Date Completed 2013-04-04
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

22563779

DOI: Digital Object Identifier

10.2174/187152812803251006

Related Literature

Article Analysis
・Side Effects of thioguanine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.